

Isolation and characterization of chemical constituents from the mushroom *Clitocybe nebularis*

Morteza YAZDANI¹ , Zoltán BÉNI² , Miklós DÉKÁNY² , Viktor PAPP³ , Andrea LÁZÁR⁵ , Katalin BURIÁN⁵ , Judit HOHMANN^{1,4*} , Attila VÁNYOLÓS^{1,6} 

¹ Department of Pharmacognosy, Interdisciplinary Excellence Centre, University of Szeged, H-6720 Szeged, Hungary.

² Spectroscopic Research Department, Gedeon Richter Plc., Gyömrői út 19-21, H-1103 Budapest, Hungary.

³ Department of Botany, Szent István University, H-1118 Budapest, Villányi út 29-43, Hungary.

⁴ Interdisciplinary Centre of Natural Products, University of Szeged, H-6720 Szeged, Hungary.

⁵ Department of Clinical Microbiology, University of Szeged, H-6720 Szeged, Hungary.

⁶ Department of Pharmacognosy, Semmelweis University, H-1085 Budapest, Hungary.

* Corresponding Author. E-mail: hohmann@pharm.u-szeged.hu (J.H.); Tel. +36-62-545 558.

Received: 26 July 2020 / Revised: 31 August 2020 / Accepted: 11 September 2020

ABSTRACT: In the course of our mycochemical studies the extract of *Clitocybe nebularis* was investigated with the aim to identify its bioactive secondary metabolites. Multistep chromatographic purification of the MeOH extract of *C. nebularis* resulted in the isolation of two steroids and an organic acid from the CHCl₃ and ethyl acetate soluble fractions. The structures of the compounds were determined by NMR and MS spectroscopy as 5 α -ergosta-7,22-diene-3 β ,5,6 β -triol (cerevissterol) (**1**), (22E,24S)-5 α -ergosta-7,22-diene-3 β ,5,6 β ,9 α -tetraol (**2**), and indole-3-carboxylic acid (**3**). The antimicrobial activity of the compounds was analyzed by agar disc diffusion method against human pathogen strains of *Streptococcus agalactiae*, *Staphylococcus epidermidis*, *Moraxella catarrhalis*, *Haemophilus influenzae*, and *Proteus mirabilis*. The susceptibility assay revealed that compounds **2** and **3** have weak antimicrobial activity against *M. catarrhalis*. The current study represents the first isolation of compounds **1-3** from *C. nebularis*.

KEYWORDS: *Clitocybe nebularis*; steroids; antimicrobial activity; Tricholomataceae.

1. INTRODUCTION

Edible and even toxic mushrooms are a valuable source of therapeutically important or nutritive compounds. Many mushroom species were reported to produce a large variety of secondary metabolites with unique chemical structures and interesting biological activities. *Clitocybe nebularis* (Batsch) P. Kumm. [syn.: *Lepista nebularis* (Fr.) Harmaja] known as clouded agaric or cloud funnel, member of the family Tricholomataceae is a common species of both conifer and broad-leaved forests in temperate and hemiboreal zones across Europe and North America [1]. *C. nebularis* is generally considered edible, but the strong, aromatic odor dissuades some people and can cause upset after consuming [2,3]. Pharmacological investigations revealed the neuroprotective, antioxidant, antimicrobial and cytotoxic properties of the acetone extract of *C. nebularis* [4] and demonstrated its significant antiproliferative and cytotoxic activities [5,6].

Previously various types of bioactive compounds have been reported from sporocarps of *C. nebularis*. Nebularine a purine riboside with bacteriostatic activity was the first biologically active compound isolated and identified from this mushroom [7]. Besides its antimicrobial activity nebularine displayed a noncompetitive inhibitory effect on xanthine oxidase [8], and possessed plant cytotoxic [9], antifungal and antibacterial properties [10,11]. In addition to nebularine, phenylacetic acid, purine, uridine, adenine, uracil, benzoic acid, and mannitol were also isolated [10]. Clitocypin, the inhibitor of cysteine proteinases has been identified in fruit bodies of *C. nebularis*, and its structure has been determined to have single protein sequence of 150 amino acids [12]. Small and stable proteins named *Clitocybe nebularis* lectin (CNL) were identified in the fruiting bodies along with several similar isolectins. CNL is a β -trefoil type lectin forming homodimers, which displays a remarkable immunostimulation of human dendritic cells, producing a strong T helper cell type 1 response. CNL therefore can be regarded as a promising candidate for different applications in medicine [13].

How to cite this article: Yazdani M, Béni Z, Dékány M, Papp V, Lázár A, Burián K, Hohmann J, Ványolós A. Isolation and characterization of chemical constituents from the mushroom *Clitocybe nebularis*. J Res Pharm. 2020; 24(6): 908-913.

Earlier studies demonstrated that cerevisterol (**1**) inhibited the growth of bacteria other than tested here (MIC value 25 µg/mL against *S. typhi*, *S. aureus* and *A. niger*, and MIC 50 µg/mL against *E. faecalis*) [29], while it was inactive against *Bacillus subtilis*, *B. pumilus*, *S. aureus*, *M. luteus*, *C. albicans* and *A. niger* at 20 µg/mL tested by disk diffusion method [30]. Similarly indol 3-carboxylic acid (**3**) was tested previously against a series of pathogenic fungi (*Fusarium avenaceum*, *F. graminearum*, *F. culmorum* and *Pyricularia oryzae*) and bacteria (*S. aureus*, *E. coli* and *B. subtilis*) but no antifungal or antibacterial activity was observed [31]. For (22*E*,24*S*)-5α-ergosta-7,22-diene-3β,5,6β,9α-tetraol (**2**) no antibacterial data are available in the literature.

Table 1. Antimicrobial activity of compounds **1-3** isolated from *C. nebularis*. (5 mg/mL concentration).

Compound	Diameter of inhibition zone (mm)				
	<i>S. agalactiae</i>	<i>S. epidermidis</i>	<i>M. catarrhalis</i>	<i>H. influenzae</i>	<i>P. mirabilis</i>
1	-	-	-	-	-
2	-	-	7	-	-
3^a	-	-	7	-	-

S. agalactiae (*Streptococcus agalactiae* ATCC 13813), *S. epidermidis* (*Staphylococcus epidermidis* ATCC 12228), *M. catarrhalis* (*Moraxella catarrhalis* ATCC 25238), *H. influenzae* (*Haemophilus influenzae* ATCC 49766), *P. mirabilis* (*Proteus mirabilis* HNCMB 60076); ^a For compound **3** 4 mg/mL concentration was used.

3. CONCLUSION

The present study provides a detailed chemical analysis of the mushroom *C. nebularis* aiming at the isolation of apolar metabolites of the MeOH extract. Further studies are required to determine how the isolated compounds contribute to other bioactivities of this species. Our data together with earlier published ones demonstrate the high diversity of compounds in *C. nebularis* and points to the potential of the mushroom as a natural source of chemical compound for pharmacological applications.

4. MATERIALS AND METHODS

4.1. General

The chemicals used in this research were provided by Molar Chemicals and Sigma-Aldrich Hungary. Flash chromatography was carried out on a CombiFlash® Rf+ Lumen Instrument with integrated UV, UV VIS, and ELS detection using reversed and normal phase flash columns filled with RediSep C18 Bulk 950 (Teledyne Isco, Lincoln, NE, USA USA) and Silica 60 (0.045-0.063 mm) (Molar Chemicals, Halásztelek, Hungary), respectively. Preparative thin layer chromatography (TLC) was performed using silica plates (20x20 cm Silica gel 60 F₂₅₄, Merck 105554).

HRMS and MS analyses were performed on a Thermo Velos Pro Orbitrap Elite and Thermo LTQ XL (Thermo Fisher Scientific) system. The ionization method was ESI operated in positive (or negative) ion mode. The (de)protonated molecular ion peaks were fragmented by CID at a normalized collision energy of 35%. For the CID experiment helium was used as the collision gas. The samples were dissolved in methanol. Data acquisition and analysis were accomplished with Xcalibur software version 4.0 (Thermo Fisher Scientific). NMR data were collected in methanol-*d*₄ at 25 °C on a Bruker 500 MHz Avance III HD spectrometer equipped with a liquid helium cooled TCI cryoprobe. Chemical shifts were referenced to residual solvent signals (3.31 (¹H) and 49.15 ppm (¹³C) MeOD-*d*₄). Standard ¹H, ¹³C, 2D-HSQC, 2D-HMBC, and ROESY data were collected in all cases using the pulse sequences available in the Topspin 3.5 pulse sequence library. The NMR assignments of all isolated compounds were in agreement with those reported earlier in the literature [17-19].

4.2. Mushroom material

Samples of *C. nebularis* (Batsch) P. Kumm. were collected in 2017 from the environs of Sándorfalva and Csákányospuszta, Hungary and identified by A. Sándor (Hungarian Mycological Society) and V. Papp. Voucher specimens have been deposited in the mycological collection of the Hungarian Natural History Museum (VPapp-1110171).

4.3. Extraction and isolation

The fresh mushroom material (5.6 kg) was extracted with MeOH (20 L) at room temperature. After concentration, the MeOH extract (54 g) was dissolved in 50% aqueous MeOH and subjected to solvent-solvent partition using *n*-hexane (5 × 500 mL), CHCl₃ (5 × 500 mL), and then EtOAc (5 × 500 mL). The CHCl₃ soluble phase (2.12 g) was separated by flash chromatography (NP-FC) on silica gel (40 g) using a gradient system of *n*-hexane-acetone (linear from 100:0 to 0:100, t = 60 min). According to TLC monitoring, fractions with similar compositions were combined (C1-C15). Fractions C7 (142 mg), C8 (108 mg) and C9 (69 mg) were further chromatographed by RP₁₈-FC (12 g) using a mixture of H₂O and MeOH (linear gradient from 40 to 90% MeOH, t = 45 min), then further purified by FC on RP₁₈ column (4 g) using H₂O-MeOH solvent system (linear gradient from 50% to 95% MeOH, t = 45 min), which resulted in the isolation of compounds **1** (31 mg) and **2** (2.7 mg). The EtOAc phase (4.15 g) was separated by NP-FC (80 g) using *n*-hexane-acetone with increasing polarity (from 100:0 to 65:35, t = 60 min), to obtain 20 major combined fractions (E1-20). Fractions E13 (33 mg), E14 (18 mg) and E15 (20 mg) were further separated by a combination of NP-FC (4 g sorbent, *n*-hexane-acetone (linear gradient from 75:25 to 30:70, t = 50 min) and preparative TLC using a CHCl₃-MeOH (97:3) solvent system to isolate compound **3** (2 mg).

4.4. Bacterial strains and culture conditions

The test microorganisms used in this study were 4 standard and 1 clinical isolate with different antibiotic resistance profile. The standard Gram-positive strains were *Streptococcus agalactiae* (ATCC 13813), and *Staphylococcus epidermidis* (ATCC 12228). The standard Gram-negative strains were *Moraxella catarrhalis* (ATCC 25238), and *Haemophilus influenzae* (ATCC 49766). *Proteus mirabilis* (HNCMB 60076) was applied as clinical strain. Bacterial cultures were grown on standard Mueller-Hinton agar (MH) and horse blood (MHF) plates at 37 °C under aerobic environment.

4.5. Determination of antibacterial activity

Screening of antibacterial activity of compounds against standard bacterial strains for their inhibition zones was carried out by standard disc diffusion method [32]. Concisely, the compounds were dissolved in DMSO at concentration 5 (**1** and **2**) and 4 (**3**) mg/mL. The bacterial suspension (inoculum 0.5 McFarland, 1–2 × 10⁸ CFU ml⁻¹) was spread on plate and the sterile filter paper discs (6 mm in diameter) impregnated with 10 µL of the compound solution was placed. DMSO served as negative control, and ampicillin, erythromycin, imipenem, cefuroxime and vancomycin were used as positive control. The plates were incubated (35 ± 2 °C for 24 h) under aerobic conditions. The diameters of inhibition zones created by the compounds (including the disc) were measured and recorded.

Acknowledgements: Financial support for this research was provided by the Economic Development and Innovation Operative Program GINOP-2.3.2-15-2016-00012, the 20391-3/2018/FEKUSTRAT. A. Ványolós is thankful for the support of the Hungarian National Research, Development, and Innovation Fund (PD 124476). The authors thank A. Sándor for his help in the collection and identification of mushroom material.

Author contributions: Concept – A.V., J.H.; Design – A.V.; Supervision – A.V., J.H.; Resource – J.H.; Materials – K.B., Z.B., A.V.; Data Collection &/or Processing – M.Y., M.D., V.P., A.L.; Analysis &/or Interpretation – M.Y., Z.B., M.D., V.P., A.L.; Literature Search – A.V., Z.B., J.H., M.Y.; Writing – M.Y., J.H.; Critical Reviews – A.V., Z.B., K.B.

Conflict of interest statement: The authors declared no conflict of interest.

REFERENCES

- [1] Knudsen H, Vesterholt J. Funga Nordica. (Vol 2). Agaricoid, Boletoid, Clavarioid, Cyphelloid and Gastroid Genera. Nordsvamp, Copenhagen: 2012. p. 1083.
- [2] Desjardin DE, Wood MG, Stevens FA. *California Mushrooms: The Comprehensive Identification Guide*. Timber Press, New York, 2015. pp. 152-153.
- [3] Kummer P. Dur Führer in die Pilzkunde. In: Luppe's Buchhandlung, Zerbst, 1871. pp. 1-146.
- [4] Kosanić M, Petrović N, Stanojković T. Bioactive properties of *Clitocybe geotropa* and *Clitocybe nebularis*. J Food Meas Charact. 2020; 14: 1046-1053. [\[CrossRef\]](#)
- [5] Bézin C, Lohézic F, Sauleau P, Amoros M, Boustie J. Cytotoxic activity of Tricholomatales determined with murine

- and human cancer cell lines. *Pharm Biol.* 2002; 40: 196-199. [CrossRef]
- [6] Pohleven J, Obermajer N, Sabotič J, Anžlovar S, Sepčič K, Kos J, Brzin J. Purification, characterization and cloning of a ricin B-like lectin from mushroom *Clitocybe nebularis* with antiproliferative activity against human leukemic T cells. *Biochim Biophys Acta.* 2009; 1790: 173-181. [CrossRef]
- [7] Lofgren N, Luning B. On the structure of nebularine. *Acta Chem Scandinav.* 1953; 7: 225.
- [8] Konuk M, Akyol O, Yilmaz K, Yildirimkaya M, Nazaroglu NK, Kisa U. Blocking of the inhibitory effect of nebularine on xanthine oxidase. *Biyokim Derg* 1996; 21: 9-15.
- [9] Brown EG, Konuk M. Plant cytotoxicity of nebularine (purine riboside). *Phytochemistry.* 1994; 37: 1589-1592. [CrossRef]
- [10] Kim Y-S, Lee I-K, Seok S-J, Yun B-S. Chemical constituents of the fruiting bodies of *Clitocybe nebularis* and their antifungal activity. *Mycobiology* 2008; 36: 110-113.
- [11] Venturini M, Rivera C, Gonzalez C, Blanco D. Antimicrobial activity of extracts of edible wild and cultivated mushrooms against foodborne bacterial strains. *J Food Protect.* 2008; 71: 1701-1706. [CrossRef]
- [12] Brzin JE, Rogelj B, Popovič T, Štrukelj B, Ritonja A. Clitocypin, a new type of cysteine proteinase inhibitor from fruit bodies of mushroom *Clitocybe nebularis*. *J Biol Chem.* 2000; 275: 20104-20109. [CrossRef]
- [13] Sabotič J, Kos J. CNL – *Clitocybe nebularis* lectin – the fungal GalNAc β 1-4GlcNAc-binding lectin. *Molecules.* 2019; 24: 4204. [CrossRef]
- [14] Caglič PA, Renko M, Turk D, Kos J, Sabotič J. Fungal β -trefoil trypsin inhibitors cnispin and cospin demonstrate the plasticity of the β -trefoil fold. *Biochim Biophys Acta Proteins Proteom.* 2014; 844: 1749-1756. [CrossRef]
- [15] Senatore F. Chemical constituents of some mushrooms. *J Sci Food Agric.* 1992; 58: 499-503. [CrossRef]
- [16] Audouin P, Vidal J, Richard H. Volatile compounds from aroma of some edible mushrooms: morel (*Morchella conica*) wood blewitt (*Lepista nuda*), clouded agaric (*Clitocybe nebularis*), and false chanterelle (*Hygrophoropsis aurantiaca*). *Sci Alim.* 1989; 185-193.
- [17] Jinming G, Lin H, Jikai L. A novel sterol from Chinese truffles *Tuber indicum*. *Steroids.* 2001; 66: 771-775. [CrossRef]
- [18] Valisolalao J, Luu B, Ourisson G. Chemical and biochemical study of Chinese drugs. Part VIII. Cytotoxic steroids from *Polyporus versicolor*. *Tetrahedron.* 1983; 39: 2779-85. [CrossRef]
- [19] Burton G, Ghini AA, Gros EG. ^{13}C NMR spectra of substituted indoles. *Magn Reson Chem.* 1986; 24: 829-831. [CrossRef]
- [20] Wang H, Ng T. Isolation of a new ribonuclease from fruiting bodies of the silver plate mushroom *Clitocybe maxima*. *Peptides.* 2004; 25: 935-939. [CrossRef]
- [21] Zhang G-Q, Wang Y-F, Zhang X-Q, Ng TB, Wang H-X. Purification and characterization of a novel laccase from the edible mushroom *Clitocybe maxima*. *Procs Biochem.* 2010; 45: 627-633. [CrossRef]
- [22] Baosong C, Sixian W, Gaoqiang L, Li B, Ying H, Ruilin Z, Hongwei L. Anti-inflammatory diterpenes and steroids from peels of the cultivated edible mushroom *Wolfiporia cocos*. *Phytochem Lett.* 2020; 36: 11-16. [CrossRef]
- [23] Ragasa CY, Tan MCS, De Castro ME, Mariquit M, Oyong GG, Shen CC. Sterols from *Lentinus tigrinus*. *Pharmacog J.* 2018; 10: 1079-1081.
- [24] Ohnuma N, Amemiy, K, Kakuda R, Yaoita Y, Machida K, Kikuchi M. Sterol constituents from two edible mushrooms, *Lentinula edodes* and *Tricholoma matsutake*. *Chem Pharm Bul.* 2000; 48: 749-751. [CrossRef]
- [25] Morelli I, Pistelli L, Catalano S. Some constituents of *Clitocybe nebularis* and of *Hydnum repandum*. *Fitoterapia.* 1981; 52: 45-47.
- [26] Chen JT, Su HJ, Huang JW. Isolation and identification of secondary metabolites of *Clitocybe nuda* responsible for inhibition of zoospore germination of *Phytophthora capsici*. *J Agric Food Chem.* 2012; 60: 7341-7344. [CrossRef]doi.org/
- [27] Fons F, Rapior S, Fruchier A, Saviuc P, Bessière JM. Volatile composition of *Clitocybe amoenolens*, *Tricholoma caligatum* and *Hebeloma radicosum*. *Cryptogamie Mycol.* 2006; 27: 45-55.
- [28] Dimitrijevic M, Jovanovic VS, Cvetkovic J, Mihajilov-Krstev T, Stojanovic G, Mitic V. Screening of antioxidant, antimicrobial and antiradical activities of twelve selected Serbian wild mushrooms. *Anal Methods.* 2015; 7: 4181-4191. [CrossRef]
- [29] Appiah T, Agyare C, Luo Y, Boamah VE, Boakye YD. Antimicrobial and resistance modifying activities of cerevisterol

isolated from *Trametes* species. *Curr Bioact Compd.* 2020; 16: 115-123. [\[CrossRef\]](#)

- [30] Guoa K, Fanga H, Guia F, Wang Y, Xua Q, Deng X. Two new ring A-ceaved lanostane-type triterpenoids and four known steroids isolated from endophytic fungus *Glomerella* sp. *Helv Chim Acta* 2016; 99: 601-607. [\[CrossRef\]](#)
- [31] Tian S, Yang Y, Liu K, Xiong Z, Xu L, Zhao L. Antimicrobial metabolites from a novel halophilic actinomycete *Nocardiopsis terrae* YIM 90022. *Nat Prod Res.* 2014; 28: 344-346. [\[CrossRef\]](#)
- [32] Bauer A, Kirby W, Sherris J, Turck M. Antimicrobial investigations. *Am J Clin Pathol.* 1966; 45: 493-496.

This is an open access article which is publicly available on our journal's website under Institutional Repository at <http://dspace.marmara.edu.tr>.